ArticleMedicine2026
Primary gastric plasmacytoma evolving to non-secretory multiple myeloma: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
rationalePrimary gastric plasmacytoma is a rare form of extramedullary plasmacytoma that may mimic gastric adenocarcinoma or lymphoma. Although it is generally considered a localized disease, delayed histologic remission after radiotherapy and subsequent systemic progression remain poorly characterized. PATIENT CONCERNS: A 75-year-old man was referred after screening endoscopy revealed an approximately 3-cm protruding gastric mass initially suspected to represent advanced gastric cancer. DIAGNOSES: Repeat biopsy demonstrated atypical plasmacytoid cell proliferation with CD138 positivity and kappa light-chain restriction. Comprehensive systemic evaluation, including bone marrow biopsy, serum and urine electrophoresis, immunofixation, serum free light-chain analysis, and PET/CT, revealed no evidence of systemic disease, supporting a diagnosis of primary gastric plasmacytoma.
interventionsDefinitive radiotherapy was delivered to the stomach at a total dose of 45 Gy in 25 fractions. OUTCOMES: Follow-up endoscopy at approximately 3 months demonstrated marked regression of the lesion; however, biopsy revealed residual monoclonal plasma cells with persistent kappa light-chain restriction. Repeat biopsy performed approximately 9 months after radiotherapy demonstrated loss of light-chain restriction with a polytypic kappa/lambda pattern, consistent with histologic remission. During subsequent follow-up, multifocal osteolytic skeletal lesions developed, and biopsy of the L5 vertebral lesion confirmed plasma cell neoplasm. Following multidisciplinary reassessment, the patient was ultimately managed as non-secretory multiple myeloma, and systemic therapy with bortezomib, lenalidomide, and dexamethasone (VRd) was initiated. LESSONS: This case demonstrates that histologic remission after radiotherapy may be delayed and that, although uncommon, systemic progression may occur despite the absence of systemic disease at initial staging. Long-term surveillance integrating clinical, radiologic, and pathologic findings is therefore essential, and early post-treatment biopsy findings should be interpreted in the context of the overall clinical course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.